InspireMD's C-GUARDIANS 12-month abstract accepted for LINC 2024; prior 30-day DSMI 0.95%

InspireMD, Inc.

Abstract of 12-month outcomes from C-GUARDIANS trial (316 patients, 24 sites) accepted for LINC 2024 (May 28-31, Leipzig).
Previously reported 30-day DSMI rate of 0.95% (ITT) and 0.63% (per-protocol).
Positive 12-month data could support PMA submission later in 2024 and potential U.S. launch of CGuard Prime in H1 2025.
Trial evaluates CGuard Carotid Stent System for carotid artery stenosis; primary endpoint includes death, stroke, MI through 365 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.